2017 ASCO Annual Meeting

Arnaud Scherpereel, MD, PhD, University Hospital of Lille, presenting Abstract LBA8507, Second or 3rd line Nivolumab (Nivo) versus Nivo plus Ipilimumab (Ipi) in Malignant Pleural Mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phas, during Monday Press Briefing

Chicago, IL - 2017 ASCO Annual Meeting - Arnaud Scherpereel, MD, PhD, University Hospital of Lille, presenting Abstract LBA8507, Second or 3rd line Nivolumab (Nivo) versus Nivo plus Ipilimumab (Ipi) in Malignant Pleural Mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phas, during Monday's Press Briefing at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Monday, June 5, 2017. Approximately 40,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 53rd Annual Meeting, which is being held at McCormick Place. The ASCO Annual Meeting highlights the latest findings in all major areas of oncology, from basic to clinical and epidemiological studies. Photo by © ASCO/Scott Morgan 2017 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org